<DOC>
	<DOCNO>NCT01815359</DOCNO>
	<brief_summary>This first randomize trial compare Early post-operative intraperitoneal chemotherapy ( EPIC ) hyperthermic intraperitoneal chemotherapy ( HIPEC ) appendiceal colorectal cancer . The purpose study find effect , good and/or bad , EPIC HIPEC cytoreductive surgery patient appendiceal , rectal colon cancer .</brief_summary>
	<brief_title>ICARuS Post-operative Intraperitoneal Chemotherapy ( EPIC ) Hyperthermic Intraperitoneal Chemotherapy ( HIPEC ) After Optimal Cytoreductive Surgery ( CRS ) Neoplasms Appendix , Colon Rectum With Isolated Peritoneal Metastasis</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Appendiceal Neoplasms</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>Patient 's age 18 year old , gender . Clinical diagnosis appendiceal colorectal neoplasm peritoneal mucinosis metastasis . Patient must plan undergo complete cytoreduction peritoneal disease . ECOG performance status ≤ 1 . Hematology : ANC ≥ 1,500/ μL ; Platelets &gt; 75,000/ μL . Adequate Renal function Creatinine &lt; 1.5 x upper limit normal ( ULN ) calculate creatinine clearance ≥ 50ml/min . Adequate Hepatic function : Bilirubin le 1.5mg/dL ; ( except patient Gilbert 's Syndrome , must total bilirubin less 3.0mg/dL ) . Women childbearing potential negative pregnancy test ( urine blood ) agree use effective contraceptive method . Reliable contraception use trial screen must continue throughout study . A woman childbearing potential define one biologically capable become pregnant . A man participate study must agree utilize reliable barrier form contraception duration study . Signed date write informed consent participate clinical trial must obtain prior study procedure . Subjects history endometrial cancer eligible present stage lower 1A histology subtype poorly differentiate . Subjects previously undergone intraperitoneal chemotherapy . Subjects classical carcinoid Tumors low malignant potential Other prior malignancy , except cure nonmelanoma skin cancer , curatively treat situ carcinoma cervix , adequately treated malignancy evidence activity 3 year indolent tumor observation three year reasonable option . Presence clinically apparent suspect metastasis sit lymph node peritoneal surface . Women pregnant lactating . Subjects condition may interfere subject ' ability understand requirement study . Known HIV Active coronary artery disease ( define unstable angina positive cardiac stress test ) . Subjects history coronary artery disease may include normal stress test within 60 day enrollment . Uncontrolled hypertension define &gt; 140/90 clear surgery time consent . New York Heart Association ( NYHA ) Class II higher Congestive heart failure . Restrictive obstructive pulmonary disease would limit study compliance place patient unacceptable risk participation study . History cerebrovascular disease . would limit study compliance place patient unacceptable risk participation study . Subjects concurrent severe medical problem unrelated malignancy would significantly limit full compliance study , place unacceptable risk participation study . Patients know floxuridine , leucovorin , mitomycin allergy . Evidence extensive intraperitoneal adhesion time surgery prohibits intraperitoneal therapy , determine operating surgeon . Any condition would preclude ability deliver appropriate IP therapy . Use oral medication , lack suitable nonoral substitute , hold ten day , would felt unacceptable risk investigator . Life expectancy &lt; 12 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ICARuS</keyword>
	<keyword>Intraperitoneal Chemotherapy</keyword>
	<keyword>hyperthermic intraperitoneal chemotherapy</keyword>
	<keyword>Optimal Surgical Debulking</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Floxuridine ( FUDR )</keyword>
	<keyword>Mitomycin</keyword>
	<keyword>12-289</keyword>
</DOC>